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Abstract Link modules are hyaluronan-binding domains that 
are involved in the formation and stability of extracellular matrix 
and cell migration. We have examined the glycosaminoglycan 
specificity of the Link module from the arthritis-associated 
protein, human TSG-6, by microtitre plate-based assays employ-
ing biotinylated-hyaluronan or mono-biotinylated Link module. 
This domain was found to interact specifically with chondroitin-
4-sulphate (C4S), with similar affinity to hyaluronan, but not 
with chondroitin-6-sulphate or heparin. Competition experiments 
indicate that C4S and hyaluronan have overlapping binding 
surfaces on the TSG-6 Link module. Disease-associated changes 
in C4S expression may influence the localisation and biological 
role of TSG-6. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The associations of glycosaminoglycans (GAGs) with pro-
teins are of functional importance in a wide range of normal 
and disease processes. For example, the interactions of 
hyaluronan'1' with hyaluronan-binding matrix proteins and 
receptors have a crucial role in the formation and stability 
of the extracellular matrix (e.g. cartilage) and in regulating 
many aspects of cell behaviour during development, morpo-
hogenesis, tumorigenesis and inflammation [1]. These interac-
tions with hyaluronan are often mediated by a protein domain 
of ~ 100 amino acids in length, termed a Link module (also 
known as a proteoglycan tandem repeat [2]). This module has 
been described in extracellular matrix molecules (link protein, 
aggrecan, versican and brevican) and the hyaluronan receptor, 
CD44. The roles of these proteins in cartilage formation and 
cell migration have been reviewed previously [1,3]. A Link 
module has also been described in the arthritis-associated pro-
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O Hyaluronan, a high molecular weight GAG found in most animal 
tissues, consists of the repeating disaccharide [D-glucuronic acid 
(Pl->3) JV-acetyl-D-glucosamine (Rl-»4)]. Unlike other GAGs (e.g. 
chondroitin sulphate, heparan sulphate) hyaluronan is not found at-
tached covalently to core proteins. 
tein product of tumor necrosis factor (TNF)-stimulated gene-
6 (TSG-6) [4]. 
There is no constitutive expression of TSG-6 mRNA in 
human fibroblasts, chondrocytes or synovial cells, but rapid 
onset of transcription and subsequent secretion of the gene 
product is seen after treatment with interleukin-1 (IL-1) or 
TNF [4-6]. In addition, the protein (which is ~ 3 5 kDa and 
mainly comprised of contiguous Link and CUB modules [4]) 
has been detected in the synovial fluids from arthritis patients 
but not from normal individuals [5]. IL-1 and TNF are well 
known to have a central role in the induction of cartilage 
breakdown in arthritis (see [7]), therefore, TSG-6 may be in-
volved in these processes [4,5]. However, in chondrocytes at 
least, TSG-6 mRNA levels are also up-regulated by trans-
forming growth factor (31, which is thought to have a role 
in cartilage repair [6]. In this regard TSG-6 has been shown 
to potentiate plasmin inhibition by inter-cc-inhibitor, with 
which TSG-6 forms a covalent complex [8]. TSG-6 has also 
been shown to have an anti-inflammatory effect in vivo by 
inhibiting neutrophil infiltration in a murine air pouch model 
[8]. 
Recently, we have described the determination of the 3-di-
mensional structure in solution, at pH 6.0, of the Link module 
from human TSG-6 (Link_TSG6) [3] expressed in E. coli [9]. 
In addition, we have demonstrated that the recombinant Link 
module interacts specifically with hyaluronan (at pH 6.0) by 
using a microtitre plate assay with biotinylated-hyaluronan 
(bHA) as a probe [3]. Elucidation of the tertiary structure 
of the Link module allowed the identification of a putative 
hyaluronan-binding surface on TSG-6 [3]. 
In this study, we demonstrate that the TSG-6 Link module 
also interacts in a specific fashion with chondroitin-4-sulphate 
(C4S), but not with chondroitin-6-sulphate (C6S) or heparin, 
at a site overlapping its hyaluronan-binding surface. 
2. Materials and methods 
2.1. Materials 
C4S (5 X 104 Da) and C6S (5 X 104 Da) were obtained from Calbio-
chem, UK (Cat. Nos. 230687 and 2307, respectively). Human umbil-
ical cord hyaluronan (mean molecular weight 4.4x10° Da), heparin 
(3 X 103 Da), and C4S/C6S (a 70 : 30 mixture of 4.6 X 104 Da C4S and 
C6S) were purchased from Sigma, UK (Cat. Nos. H1876, H3400 and 
C8529, repectively). NHS-LC-biotin and trifluoroacetic acid (TFA) 
were supplied by Pierce, UK. Acetonitrile was purchased from Rath-
burn, UK. Microtitre plates and development reagents used in the 
binding assay were as described previously [3]. The Link module 
from human TSG-6 (denoted Link_TSG6), corresponding to amino 
acids 36-133 in the preprotein [4], was expressed and purified as 
described before [9,10]. Biotinylated hyaluronan (250 kDa) was pre-
pared as in Kohda et al. [3]. The Gl domain of aggrecan, purified 
from porcine laryngeal cartilage by the method of Bonnet et al. [11], 
was a kind gift of Ms. Sarah Howat and Dr. Mike Bayliss (Kennedy 
Institute of Rheumatology, London). 
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2.2. Biotinylation of Link_TSG6 
Equal volumes (400 ul) of Link_TSG6 (2.5 mg/ml in H 2 0) and a 
fresh solution of NHS-LC-biotin (222 ug/ml) in 100 mM NaHC0 3 
pH 8.5 were mixed for 1 h at room temperature. The reaction mixture 
was centrifuged (5 min, 12000Xg) to remove any precipitate (hydro-
lysed biotin reagent) and 2 ml of solvent A [0.1% (v/v) trifluoroacetic 
acid (TFA)] was added to the supernatant. Biotinylated protein was 
purified by high-performance liquid chromatography (HPLC) on a 
250x7.0-mm Aquapore RP-300 (300 A, 7 urn) column (Applied Bio-
systems, UK), equilibrated in 80% (v/v) solvent A, 20% (v/v) solvent B 
[80% (v/v) acetonitrile, 0.09% (v/v) TFA] at a flow rate of 2.5 ml/min. 
After injection of the sample initial conditions were maintained for 10 
min, followed by linear gradinets of 20-40, 40^15 and 45-95% (v/v) 
solvent B (in solvent A) over 15, 10 and 5 min, respectively. The 
absorbance at 220 nm was continuously monitored and peaks (I-
IV) were collected manually. Protein was recovered from these peaks 
by drying in a SpeedVac (Savant) and analysed by electrospray ion-
isation mass spectrometry (ESI-MS) as described in Day et al. [9]. 
Mono-biotinylated species were resuspended in H2O and repurified 
by HPLC using the conditions described above. These species were 
stored as HPLC eluates at 4°C and aliquots were dried in a SpeedVac 
as required. The mono-biotinylated species, bA-Link_TSG6, was used 
in the binding assay described below (Section 2.4). 
2.3. Binding assay with biotinylated-hyaluronan 
The effect of glycosaminoglycan competition on the binding of 
biotinylated-hyaluronan (bHA: 250 kDa) to immobilised Link_TSG6 
or Gl-aggrecan was investigated using a modification of the assay 
described in Kohda et al. [3]. All dilutions, incubations, and washes 
were performed in Standard Assay Buffer (50 mM Na-acetate, 100 
mM NaCl, 0.05% (v/v) Tween 20 pH 5.8) at room temperature unless 
otherwise stated. Plastic Linbro microtitre plates (EIA II Plus) were 
coated overnight with 200 ul/well of protein solution (containing 18 or 
22 pmol of Gl-aggrecan or Link_TSG6, respectively) in 20 mM 
Na2CC>3 pH 9.6. Control wells were incubated with buffer alone. 
The coating solution was removed and the plates were washed 3X. 
Non-specific binding sites on the plate were blocked by incubation for 
90 min at 37°C with 1% (w/v) bovine serum albumin, followed by 
three washes. A 200 |il solution of 12.5 ng bHA (33 pmol when ex-
pressed as disaccharide equivalents)'2' alone, or containing various 
amounts of unlabelled GAGs (hyaluronan, heparin, C4S/C6S, C4S 
or C6S: in the ranges 1.60 to 4380 and 13.22 to 21900 pmol 
DSequiy, for Link_TSG6 and Gl-aggrecan coated wells, respectively), 
was added to each well and incubated overnight. Plates were washed 
3X, and 200 ul of a 1 in 10000 dilution of Extra-Avidin alkaline 
phosphatase was added and incubated for 30 min, followed by three 
washes. A 1 mg/ml solution (200 ul/well) of disodium p-nitrophenyl-
phosphate, in 100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 
9.3, was added to all wells and incubated until sufficient colour had 
developed (18-60 min). The absorbance at 405 nm was determined on 
a microtitre plate reader (MKII Titertek Multiscan Plus). All absorb-
ances were corrected against blank wells which contained substrate 
solution alone and were then standardised to a 10 min development 
time. 
2.4. Assay with biotinylayed Link module of TSG-6 
This assay measures the binding of mono-biotinylated Link_TSG6 
(bA-Link_TSG6) to microtitre wells coated with either hyaluronan or 
C4S in the absence or presence of unlabelled hyaluronan or C4S in 
solution. The assay was performed as above (Section 2.3), but with 
0.2% (v/v) Tween 20 in the Standard Assay Buffer. Wells were coated 
separately with 5 ug hyaluronan (13.2 nmol DSequ;v), 6.05 ug C4S 
(13.2 nmol DSequiV) or coating solution alone. Plates were washed 
and blocked as before. A 200 ul solution of 21.9 ng bA-Link_TSG6 
(2 pmol), containing either no GAG or 0.1 to 100 ng hyaluronan 
(0.264-264 nmol DSequiT), or 0.1 to 100 ug C4S (0.219-219 nmol 
DSequiy) was added to each well. The plates were incubated, washed, 
and developed as descibed in Section 2.3. 
'2 ' Due to the wide range of GAG molecular weights used in this 
study, and incomplete information on the size of GAG oligomer that 
are recognised by the proteins, they are expressed throughout as mo-
lar disaccharide equivalents (DSequ;v). 
3. Results 
The Link module from human TSG-6 (Link_TSG6) was 
biotinylated with NHS-LC-biotin, and purified by reverse-
phase HPLC, on an Aquapore RP-300 column, as shown in 
Fig. 1. Four major species (peaks I-IV) elute from the column 
and the peak at ~ 40 min is derived from the system (i.e. it is 
present in all blank runs). Protein was recovered from peaks 
I-IV by drying in a SpeedVac and analysed by ESI-MS (data 
not shown). Species I has a molecular mass identical to that of 
wild-type Link_TSG6 (10922.5 Da) [9]. The molecular masses 
of species II and III are both 11262.5 Da (wild-type+340 Da). 
Since 340 Da is the mass of the biotin moeity, species II and 
III correspond to mono-biotinylated forms of the protein (de-
noted bA- and bB-Link_TSG-6, respectively), where the bio-
tin is likely to be attached at different sites given their different 
elution volumes. Species IV has a molecular mass of wild-
type+680 Da, which is consistent with it being di-biotinylated. 
The effects of heparin or chondroitin-sulphate on the bind-
ing of bHA to immobilised Gl-aggrecan, or Link_TSG6, were 
investigated (Section 2.3). Fig. 2a shows that unlabelled hya-
luronan can compete the bHA binding to Gl-aggrecan as 
shown previously [3] with an IC50 of ~825 pmol DSequiv 
(310 ng). A mixture of C4S and C6S (C4S/C6S) was also 
found to compete for this interaction, but only when it was 
present at significantly higher concentrations (ICso~21895 
pmol DSequ;v). Heparin was found to have no effect on the 
interaction between bHA and Gl-aggrecan even when in a 
very large excess (Fig. 2a). Similarly, the interaction of bHA 
with Link_TSG6 was not competed by heparin (Fig. 2b). This 
interaction, however, could be inhibited by C4S/C6S with IC50 
values of the same order of magnitude as with hyaluronan 
(~79 and 100 pmol DSequiv, respectively). Therefore, the as-
say was performed with either C4S or C6S, separately, to test 
which of these components were responsible for the inhibi-
tion. As shown in Fig. 2b, high levels of C6S were necessary 
to produce a small reduction in bHA binding, whereas, the 
interaction could be completely inhibited by C4S at similar 
concentrations (IC50 ~ 40 pmol DSequiv) to that seen with hy-
aluronan. The slight inhibition seen with C6S may be due to a 
small amount of C4S in this GAG preparation. 
The interactions of Link_TSG6 with C4S and hyaluronan 
were investigated further using a different plate assay as de-
scribed in Section 2.4. This assay measures the effect of C4S 
and hyaluronan on the binding of mono-biotinylated 
Link_TSG6 (bA-Link_TSG6) to C4S, or hyaluronan, coated 
plates. From Fig. 3 it can be seen that bA-Link_TSG6 binds 
to hyaluronan coated wells and this interaction can be fully 
competed by either hyaluronan or C4S, in solution, with IC50 
values of 1.50 and 3.73 nmol (DSequiv), respectively. The other 
mono-biotinylated form of the Link module (bB-Link_TSG6) 
was also shown to interact specifically with hyaluronan (data 
not shown), but was not investigated further. Fig. 3 shows 
that bA-Link_TSG6 can bind directly to a C4S coated plate 
and this interaction can be competed with similar concentra-
tions of either C4S or hyaluronan (IC50 values of ~ 7.75 and 
6.23 nmol DSequiv, repectively). In this assay there is ~ 2 X 
greater binding of bA-Link_TSG6 to wells coated with C4S 
than with hyaluronan in the absence of competitor. Given the 
similarity of the competition curves with C4S and hyaluronan, 
in each case, the level of bA-Link_TSG6 binding may reflect 
different coating efficiencies of the two GAG preparations. 
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Fig. 1. Purification of biotinylated Link_TSG6 by reverse-phase HPLC on a Aquapore RP-300 column monitored at 220 nm. The elution gra-
dient, which resolved four major species (denoted I-IV), is shown by a dotted line with the percentage of solvent B shown on the right side. 
4. Discussion 
We have investigated the specificity of GAG binding to the 
Link module of TSG-6 in comparison with that of the Gl 
domain of aggrecan. The binding assays were conducted at 
pH 5.8 as there is maximal binding of Link_TSG6, and close 
to maximal binding of Gl-aggrecan, to hyaluronan at this pH 
(A.A. Parkar, J.D. Kahmann, S.L.T. Howat, M.T. Bayliss, 
I.D. Campbell and A.J. Day, manuscript in preparation). In 
a competition assay the interaction between bHA and a 
Link_TSG6 coated plate can be effectively inhibited by similar 
concentrations of hyaluronan and C4S, but not by C6S or 
heparin (Fig. 2b). The interaction between bHA and Gl-ag-
grecan was also found to be unaffected by heparin, but was 
inhibited with C4S/C6S where the IC50 was > 25-fold higher 
than with hyaluronan (Fig. 2a). In this case competition as-
says with the individual chondroitin sulphate isoforms were 
not performed. To determine whether the effect of C4S on the 
interaction of hyaluronan with Link_TSG6 was an artefact of 
the protein being immobilised on a micotitre plate, an assay 
was developed that employs mono-biotinylated Link_TSG6 
(bA-Link_TSG6), in solution, binding to a hyaluronan coated 
plate (Fig. 3). In this assay both GAGs can inhibit the inter-
action which is consistent with the results of the previous 
binding assay (see Fig. 2b) and demonstrates that C4S can 
inhibit the binding of hyaluronan to Link_TSG6 irrespective 
of whether the protein is immobilised or in solution. In addi-
tion, bA-Link_TSG6 was found to bind directly to a C4S 
coated plate and this interaction could be inhibited by C4S 
and hyaluronan with similar IC5o values (Fig. 3). These data 
clearly demonstrate that C4S interacts specifically with 
Link_TSG6 and strongly suggests that it is a novel ligand 
for TSG-6. Previously, Lee et al. [4] reported that a full-length 
recombinant human TSG-6, expressed in a fibroblast cell line, 
does not bind to C4S/C6S as these species did not co-precip-
itate in the presence of the cationic detergent cetylpryidinium 
chloride, but TSG-6 did co-precipitate with hyaluronan under 
the same conditions. It is difficult to comment on the apparent 
discrepancy between the results of Lee et al. [4] and the data 
presented here, as their material was only partially purified 
(on hyaluronan-sepharose) and analysed by SDS-PAGE 
alone, whereas the recombinant Link module we used has 
been rigorously investigated [9] and its tertiary structure de-
termined by NMR [3]. In both our plate-binding assays C4S 
and hyaluronan bind to Link_TSG6 competitively, indicating 
that their binding surfaces on the Link module are at least 
overlapping and possibly identical. Given the similar nature of 
the competition curves for the two GAGs, in both assays 
(Figs. 2 and 3), their affinities are also likely to be very similar. 
However, as the sizes of C4S and hyaluronan oligomers rec-
ognised by Link_TSG6 are not yet known, and are conceiv-
ably different, it is not possible at present to determine 
whether their affinities are identical. 
Chondroitin sulphate and hyaluronan are highly related 
GAGs with the same type of glycosidic linkages. The only 
difference between the disaccharide unit of hyaluronan and 
C4S is the nature and orientation of the functional group 
attached at the C4 position of the amino-sugar. In hyaluronan 
this is a hydroxyl group in the equatorial position, whereas 
C4S has an axial sulphate group. The data presented here 
suggests that the equatorial C4 hydroxyl groups in hyalur-
onan may not be involved in the interaction with Link_TSG6 
as they can be 'replaced' by axial sulphates in C4S without 
affecting the binding. Conversely, the C6 hydroxyls of hyalur-
onan are likely to be of functional importance in this inter-
action, as the presence of a sulphate group on the C6 posi-
tions (as in C6S) effectively abolishes Link_TSG6 binding. 
Work is currently in progress to elucidate the tertiary struc-
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Fig. 2. Binding of bHA to Gl-aggrecan (a) or Link_TSG6 (b) coated microtitre plates in the absence (*) or presence of unlabelled GAGs 
(B, hyaluronan; ♦, heparin; 0 , C4S/C6S; v , C4S; A, C6S) at pH 5.8. Binding was determined colorimetrically, by absorbace at 405 nm 
(after 10 min development time) and values are plotted as mean percentages (ft = 3, ±S.E.M.) of binding in the absence of competing GAG. 
ture of Link_TSG6 complexed with hyaluronan. This should 
allow us to determine how this Link module can recognise 
C4S, but be unable to bind C6S. 
On the basis of the competition studies presented here Gl -
aggrecan also binds to chondroitin sulphate, but with signifi-
cantly lower affinity than to hyaluronan, and the GAG-bind-
ing sites are again likely to be overlapping. However, it has 
been previously shown in a similar assay, employing biotiny-
lated-Gl-aggrecan binding to a hyaluronan coated plate, that 
chondroitin sulphate had no effect on this interaction even 
when present in large excess [12]. The reason for this apparent 
difference is not clear, but could relate to differences in the 
chondroitin sulphate preparations used. Chondroitin sulphate 
binding to cartilage link protein and CD44 have also been 
investigated previously. Bovine link protein did not bind to 
either C4S or C6S [13]. CD44, however, has been shown to 
bind C4S, but in this case the interaction was ~ 100X weaker 
than with hyaluronan [14]. CD44 was also found to bind very 
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weakly to C6S, but not to heparin. Other studies have shown 
that both C4S and C6S can block the binding of soluble 
CD44 to cultured lymph node high endothelial cells, but 
~ 100-fold less effectively than hyaluronan [15]. Recently, 
CD44 has been shown to interact with a C4S proteoglycan, 
serglycin, which is secreted by hematopoetic cells and may be 
involved in the activation and adhesion of cytotoxic T lym-
phocytes [16]. The interaction between serglycin and CD44 
could be inhibited by hyaluronan in a dose dependent manner 
indicating that the serglycin- and hyaluronan-binding sites on 
CD44 are likely to be overlapping. The binding of CD44 to 
serglycin was found to be mediated by C4S, but this interac-
tion only had high affinity when the C4S was associated with 
the protein core. 
As described above, TSG-6 production is induced by IL-1 
and TNF in cells of articular joints [4-6]. Importantly, expres-
sion of C4S epitopes are also affected by these inflammatory 
mediators. IL-1 increases the level of C4S in cartilage, while 
reducing the production of C6S [17]. Increased levels of C4S 
(but not C6S) have also been found, on the GAG chains of 
the proteoglycan aggrecan, in articular cartilage from osteo-
arthritis patients compared to normals [18]. In normal human 
synovium, C4S is distributed evenly throughout the interstitial 
matrix, however, in rheumatoid synovium levels of C4S are 
reduced in the matrix while becoming localised to blood vessel 
walls [19]. In this regard, it is interesting to note that the 
rabbit orthologue of TSG-6 (PS4, which has 94% sequence 
identity with the human protein [20]) is expressed by vascular 
smooth muscle cells in response to IL-1 [21]. Therefore, these 
disease-associated changes in C4S distribution in cartilage and 
synovium may affect the localisation and thus the biological 
role of TSG-6. In addition, the expression and secretion of 
TSG-6 by peripheral blood monocytes is greatly up-regulated 
by lipopolysaccharide [4,5], which also increases the secretion 
of the CD44 ligand serglycin from macrophages [22]. It is 
possible, therefore, that TSG-6 could be involved in modulat-
ing certain aspects of CD44 function, for example the ser-
glycin-mediated activation of cytotoxic T lymphocytes. 
Here we have shown that the Link module of human TSG-
6 can interact specifically with C4S at a site that is overlap-
ping with its hyaluronan-binding surface. At present the bio-
logical relevance of the interaction between TSG-6 and C4S is 
not known. However, C4S-proteoglycans that are upregulated 
in inflammation should be considered as good candidates for 
TSG-6 ligands. In inflammation, changes in the expression of 
GAGs and GAG-binding proteins may be involved in modu-
lating matrix breakdown and the migration of specific leuko-
cyte populations into the tissues. 
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